INS and breast cancer: Its favorable safety profile, especially with regard to breast cancer, veno-thromboembolism risk and metabolic profile (i.e. insulin resistance, lipid profile, blood pressure, renal function), makes MP a good therapeutic option particularly in case of patients who present an increased risk of cardiovascular and all-cause mortality (Turner syndrome, menopause) [56, 58, 100, 128].